About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Reality and Expectations
The cost of DNA sequencing has dropped dramatically since the completion of the Human Genome Project in 2003. However, many barriers need to be overcome in order to translate pharmacogenomic research findings into clinical practice.
C. Lee Ventola, MS
A History of REMS Requirements, a Review of the Data, and an Approach to Compliance in the Hospital
Risk Evaluation and Mitigation Strategy (REMS) programs now accompany more than 150 drug products. The ESA APPRISE Oncology Program was implemented to ensure the safe use of erythropoiesis-stimulating agents (ESAs). One hospital’s response to the challenge of meeting compliance criteria involved the creation of a specific medication order set.
David J. Reeves, PharmD, BCOP; Amanda K. Quebe, PharmD; and Ranita Patel, PharmD
Newer-generation branded proton pump inhibitors (PPIs) have shown some advantages over generic PPIs in the treatment of gastroesophageal reflux disease. These differences are discussed along with ways of incorporating the newer PPIs into formularies.
David A. Peura, MD; Rosemary R. Berardi, PharmD; Javier Gonzalez, PharmD; and Louis Brunetti, MD, JD
American Society of Hypertension and European Congress of Rheumatology/European League Against Rheumatism
Sessions on hypertension focus on four fixed-dose clinical trials and the effects of coffee and caffeine. The EULAR meeting includes news about pegloticase (Krystexxa) for gout; tofacitinib, an investigational oral biologic for rheumatoid arthritis; and anti–tumor necrosis factor therapy for arthritis.
Confusion of Micrograms With Milligrams
A fatal zinc overdose in a newborn caused by confusion of micrograms versus milligrams
Matthew Grissinger, RPh, FASCP
Slow Review Time and Safety Are at Issue
FDA approvals, drug indications, and updates
Fidaxomicin (Dificid) for fecal incontinence, rilpivirine (Edurant) for HIV-1 infection, and boceprevir (Victrelis) for patients with chronic hepatitis C virus genotype 1 infection
Marvin M. Goldenberg, PhD, RPh, MS